• Like

Loading…

Flash Player 9 (or above) is needed to view presentations.
We have detected that you do not have it on your computer. To install it, go here.

AROMASIN® (exemestane): Adjuvant Therapy for Early Stage ...

  • 668 views
Uploaded on

 

  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads

Views

Total Views
668
On Slideshare
0
From Embeds
0
Number of Embeds
0

Actions

Shares
Downloads
40
Comments
0
Likes
0

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. AROMASIN ® (exemestane): Adjuvant Therapy for Early Stage Breast Cancer After 2 to 3 Years of Tamoxifen Please see full prescribing information.
  • 2. Breast Cancer
    • Breast cancer is the most commonly diagnosed cancer among women in the United States
    • It is estimated that 212,930 new cases and 40,870 deaths will result from breast cancer in 2005
    • About 3/4 of breast cancers are estrogen receptor (ER) – and/or progesterone receptor (PR) – positive and are, therefore, suitable for hormonal therapy
    • The majority of women diagnosed with breast cancer are postmenopausal
    American Cancer Society. Cancer Facts and Figures 2005. Atlanta, Ga: American Cancer Society, Inc.; 2005 ; Johnston et al. Nat Rev Cancer. 2003;3 : 821-831.
  • 3. Hormonal Therapy Options LHRH = luteinizing hormone-releasing hormone. Hayes DF et al. In: Robertson et al, eds. Endocrine Therapy of Breast Cancer . 2002:3-10. Robertson JF. Clin Ther . 2002;24(suppl A):A17-A30. Androgens, progesterone, progestational agents Other LHRH analogues, radiation, surgery Hormonal ablation (premenopausal women) Aromatase inhibitor/inactivator (AI) Estrogen synthesis suppression (postmenopausal women) Selective estrogen-receptor down-regulators (SERDs) Selective estrogen-receptor modulators (SERMs) ER blockade Therapeutic Modality Examples Mechanism
  • 4. Tamoxifen Has Been the Standard of Care
    • 21%, 28%, and 50% relative risk reduction in 1-year, 2-year, and 5-year trials of tamoxifen therapy over placebo, respectively
    • 28% reduction of death with 5 years of tamoxifen therapy over placebo
    • 47% relative risk reduction of contralateral breast cancer with 5 years of therapy over placebo
    • Current standard of tamoxifen treatment is 5 years. However, the absolute benefit per year decreases over the duration of therapy
    Early Breast Cancer Trialists’ Collaborative Group. Lancet . 1998;351:1451-1467. Fisher B et al. J Natl Cancer Inst. 2001;93:684-690. Meta-analysis of 55 trials and approximately 30,000 women with ER+ tumors :
  • 5. Resistance to Tamoxifen Over Time Hypothetical Model Based on Clinical Observation Mamounas E. Oncology (Huntingt) . 2001;15:35-39. ER+, Sensitive to Tamoxifen ER+, Stimulated by Tamoxifen Year ER+ Micrometastases (%)
  • 6. Tamoxifen Has Both Antagonist and Agonist Effects Riggs L et al. N Engl J Med. 2003;348:618-629. Johnston SRD et al. Nat Rev Cancer . 2003;3:821-831. Tamoxifen Antagonis t Agonist
    • Tumor inhibition
    • Hot flashes
    • Potential tumor stimulation
    • ↑ Risk of endometrial cancer and thromboembolic effects
    • Lowers cholesterol
    • Preserves bone density
  • 7. Aromatase Inhibition and Inactivation: Mechanism of Action Estrone Estradiol Testosterone AIs and inactivators Androstenedione Cholesterol
    • Cortisol
    Progesterone Aldosterone Pregnenolone Aromatase Miller WR et al. Cancer Control. 2002;9(suppl):9-15. Aromatase
  • 8. Differences in AI and Tamoxifen Mechanism of Action EREs = estrogen response elements. Johnston SRD et al. Nat Rev Cancer. 2003;3:821-831. Adapted with permission: http://www.nature.com. Androgens AI (eg, exemestane) Aromatase Estrogens Tamoxifen
    • Proliferation
    ER target genes EREs ER ER
  • 9. Differences in the Structures of Aromatase Inhibitors and Inactivators* Androstenedione Steroidal (inactivators) Androgen substrate Nonsteroidal (inhibitors) H O O *The clinical significance of these differences is unknown. Goss PE et al. J Clin Oncol. 2001;19:881-894; Goss P. Available at: http://www.medscape.com/viewprogram/1022_pnt. Accessed September 26, 2005. Aminoglutethimide O NH 2 C 2 H 5 O N Exemestane O CH 2 O Formestane O OH O Letrozole CN NC N N N Anastrozole CH 3 CH 3 CH 3 CH 3 N N N CN NC
  • 10. AROMASIN ® (exemestane) Tablets: Adjuvant Indication
    • AROMASIN is indicated for adjuvant treatment of postmenopausal women with ER+ early breast cancer who have received 2 to 3 years of tamoxifen and are switched to AROMASIN for completion of a total of 5 consecutive years of adjuvant hormonal therapy.
    Please see full prescribing information.
  • 11. Important Safety Considerations
    • AROMASIN ® (exemestane) should not be used in women who are
      • Premenopausal
      • Nursing or pregnant
      • Known to be hypersensitive to the drug
      • Taking estrogen-containing agents
    • For patients receiving exemestane with a potent CYP 3A4 inducer, such as rifampicin or phenytoin, the recommended dose of exemestane is 50 mg qd after a meal
    • In patients with early breast cancer, elevations in bilirubin, alkaline phosphatase, and creatinine were more common in those receiving AROMASIN
    • Reductions in bone mineral density over time are seen with use of AROMASIN
    Please see full prescribing information.
  • 12. IES Trial Design Multinational, Double-Blinded, Randomized, Landmark Trial RANDOM I ZAT I ON Diagnosis and Initial Treatment of Early Breast Cancer Tamoxifen 2 to 3 years 20 mg po qd* (n = 2372) AROMASIN ® 2 to 3 years 25 mg po qd (n = 2352) Total of 5 Consecutive Years of Hormonal Therapy Tamoxifen Therapy 2 to 3 years N = 4724 Patient stratification: Node status Prior chemotherapy (CT) Hormone receptor status *Approximately 3% of patient population received tamoxifen 30 mg po qd. Median follow-up 34.5 months. Please see full prescribing information. Patient Ends Therapy and Continues Follow-up
  • 13. IES: Collaboration Between 20 International Trials Groups A total of 367 hospitals in 37 countries Total number of patients = 4740 United States 364 South American Argentina 148 Peru 7 Africa South Africa 19 Egypt 7 Australia Australia 48 New Zealand 22 Asia Hong Kong 6 Europe United Kingdom 594 Ireland 58 France 398 Belgium 171 Switzerland 55 Germany 185 Denmark 136 Greece 41 Italy 616 Luxembourg 4 Netherlands 306 Bulgaria 83 Croatia 117 Czech Republic 64 Estonia 5 Hungary 77 Russia 48 Slovakia 61 Slovenia 40 Yugoslavia 41 Romania 63 Poland 311 Spain 254 Portugal 28 Malta 12 Norway 126 Sweden 163 Israel 62 Bosnia 2 Data on file. Pfizer Inc, New York, NY.
  • 14. IES Study End Points
    • Primary end point
      • Disease-free survival (DFS) defined as:
        • Breast cancer recurrence at any site
        • Contralateral breast cancer (CLBC) (second primary)
        • Death from any cause (prior to breast cancer recurrence)
    • Secondary end points
      • Overall survival
      • Distant RFS
      • Contralateral breast cancer
      • Long-term tolerability
    Coombes RC et al. N Engl J Med . 2004;350:1081-1092.
  • 15. IES Key Entry Criteria
    • Inclusion criteria
      • 2 to 3 years of adjuvant tamoxifen therapy
      • Confirmed postmenopausal status at time of diagnosis
      • Previous CT permitted
      • ER+/ER unknown status
    • Exclusion criteria
      • Known ER – status
      • Clinical evidence of local relapse or distant metastases
      • Osteoporosis and/or osteoporotic fractures
    Data on file. Pfizer Inc, New York, NY. Coombes RC et al. N Engl J Med . 2004;350:1081-1092.
  • 16. Patient Characteristics *Includes not reported, unknown, or missing nodal status. Please see full prescribing information. 98.4 1.6 98.4 1.6 Race (%) Caucasian Other (including Hispanic, Asian, Black) 32.4 67.6 32.9 67.1 Adjuvant Chemotherapy (%) Yes No 51.8 44.0 29.8 10.3 3.6 4.5 51.7 44.7 30.7 10.2 3.7 3.7 Nodal status (%) Negative Positive 1 to 3 nodes positive 4 to 9 nodes positive >9 nodes positive Other* 63 63 Demographics Median age, years Continue on Tamoxifen (n = 2372) Switch to AROMASIN ® (n = 2352) Characteristic
  • 17. Patient Characteristics (cont’d) *These include patients with tumors for which the ER status was unknown at randomization. Please see full prescribing information. 77.2% 13.5% 9.0% 75.6% 14.5% 9.8% Histologic type (%) Infiltrating ductal Infiltrating lobular Other Continue on Tamoxifen (n = 2372) Switch to AROMASIN ® (n = 2352) Characteristic 55.6% 29.2% 15.2% 12.3% 0.3% 2.4% 0.2% 56.6% 28.8% 14.6% 12.2% 0.3% 2.0% 0.1% ER status* (%) ER+/PR+ ER+/PR– or PR-unknown Other ER unknown/PR+ or PR unknown ER–/PR+ ER–/PR– or PR unknown Missing
  • 18. Results From the 34.5 Month Follow-up: Label Data and NEJM Publication
    • N Engl J Med publication, March 2004 (N = 4742*; median f/u 30.6 mo; events = 449)
      • Cutoff date June 30, 2003
      • Events received by cutoff date
      • Safety reported as incidence case analysis after randomization
    • FDA approved label (N = 4740; median f/u 34.5 mo; events = 520)
      • Cutoff date June 30, 2003
      • Events occurred by cutoff date
      • Safety reported as treatment emergent
    *2 patients were found to be counted twice. f/u = follow-up. Data on file. Pfizer Inc, New York, NY; Coombes RC et al. N Engl J Med . 2004;350:1081-1092. Please see full prescribing information.
  • 19. Number of Events to DFS at 34.5 Months * Includes deaths for other reasons and deaths missing or unknown. Please see full prescribing information. 520 307 (13.0%) 213 (9.1%) Total number of events 1 0 1 (0.04%) Ipsilateral breast cancer 99 54 (2.3%) 45 (1.9%) Deaths of any cause * 32 25 (1.0%) 7 (0.3%) Second primary —CLBC 309 183 (7.7%) 126 (5.4%) Distant recurrence 79 45 (1.9%) 34 (1.5%) Local-regional recurrence Total Continue on Tamoxifen (n = 2372) Switch to AROMASIN ® (n = 2352)
  • 20. Efficacy Results: ITT Population ITT = intent-to-treat; HR = hazard ratio; CI = confidence interval; NS = not significant. NS 0.67-1.10 0.86 Overall survival .002 0.62-0.90 0.74 Distant RFS .0034 0.15-0.72 0.32 CLBC .00003 0.58-0.82 0.69 DFS P Value 95% CI HR ITT Population
  • 21. Efficacy Results: Hormone-Receptor Positive Patients Please see full prescribing information. NS 0.67-1.17 0.88 Overall survival .00367 0.59-0.90 0.73 Distant RFS .00069 0.08-0.57 0.22 CLBC .00001 0.53-0.79 0.65 DFS P Value 95% CI HR Hormone-Receptor Positive Patients
  • 22. Disease-Free Survival Months From Randomization Patients, DFS (%) 0 20 40 60 10 30 50 70 AROMASIN ® ITT Population Tamoxifen Please see full prescribing information. HR = 0.69 (0.58-0.82) P = .00003 100 80 60 40 20 0 13% 307 Tamoxifen (n = 2372) 9% 213 AROMASIN (n = 2352) Patients Events Median follow-up = 34.5 months
  • 23. DFS Subgroup Analysis: Forest Plot *P = .00003; CT = chemotherapy; PgR = progesterone receptor. Data on file. Pfizer Inc, New York, NY. Please see full prescribing information. HR Log Scale 0.4 0.6 0.8 1.0 1.2 Hazard Ratio HR (95% CI) 0.69 (0.58-0.82)* 0.70 (0.56-0.88) 0.67 (0.51-0.88) 0.67 (0.46-0.96) 0.63 (0.46-0.85) 0.74 (0.54-1.02) 0.65 (0.53-0.79) Subgroup All patients No previous CT Previous CT 4-9 nodes positive 1-3 nodes positive Nodes negative ER and/or PgR+ >9 nodes positive 0.62 (0.36-1.07) 1.4 ER+/PgR – ER+/PgR+ 0.66 (0.51-0.84) 0.68 (0.45-1.02 )
  • 24. Overall Survival Months From Randomization Patients Surviving (%) 0 20 40 60 10 30 50 70 Tamoxifen AROMASIN ® Data on file. Pfizer Inc, New York, NY. Please see full prescribing information. ITT Population HR = 0.86 (0.67-1.10) P = NS 100 80 60 40 20 0 6% 137 Tamoxifen (n = 2372) 5% 116 AROMASIN (n = 2352) Patients Deaths Median follow-up = 34.5 months
  • 25. Incidence (%) of Adverse Events*: All Grades *Adverse events occurring ≥5%. † Statistically significant. Please see full prescribing information. Continue on Tamoxifen (n = 2280) Switch to AROMASIN ® (n = 2252) Body System and Adverse Event 19.9% 8.4% 8.7% 8.6% 6.4% 7.2% 4.5% 14.7% 21.2% 9.8% 8.5% 14.6% † 9.0% † 8.6% 5.9% 16.1% Vascular Hot flushes Hypertension Musculoskeletal Arthralgia Pain in limb Back pain Osteoarthritis General Disorders Fatigue Gastrointestinal Nausea
  • 26. Incidence (%) of Adverse Events*: All Grades *Adverse events occurring ≥5%. † Statistically significant. Please see full prescribing information. Continue on Tamoxifen (n = 2280) Switch to AROMASIN ® (n = 2252) Body System and Adverse Event 3.8% 10.4% 8.9% 5.6% 10.8% 8.4% 5.0% 11.8% 12.4% † 6.2% 13.1% 9.7% Eyes Visual disturbance Psychiatric Insomnia Depression Nervous Headache Dizziness Skin Sweating increased
  • 27. Exemestane and Tamoxifen: Comparison of Adverse Events*
    • Exemestane was associated with a higher incidence of:
      • Osteoporosis (4.6% vs 2.8%)
      • Osteochondrosis and trigger finger (0.3% vs 0%)
      • Paresthesia (2.6% vs 0.9%)
      • Carpal tunnel syndrome (2.4% vs 0.2%)
      • Neuropathy (0.6% vs 0.1%)
      • Diarrhea (4.2% vs 2.2%)
    • Tamoxifen was associated with a higher incidence of:
      • Muscle cramps (3.1% vs 1.5%)
      • Thromboembolism (2.0% vs 0.9%)
      • Endometrial hyperplasia (1.7% vs 0.6%)
      • Uterine polyps (2.4% vs 0.4%)
    *Events occurring at a rate of <5%. Please see full prescribing information.
  • 28. Other Event Rates *Events include: myocardial infarction, angina, and myocardial ischemia. Please see full prescribing information. 0.3% 1.4% .1% .1% 0.4% 1.3% .3% .2% Incidence of observed cardiac failure Deaths due to any cause Deaths due to stroke Deaths due to cardiac failure 0.6% 1.6% Incidence of cardiac ischemic events* Continue on Tamoxifen (n = 2372) Switch to AROMASIN ® (n = 2352) Adverse Event 5.1% 6.3% Discontinuation rate
  • 29. AROMASIN ® (exemestane) Bone Profile Was Investigated in 2 Well-Controlled Studies * For patients who had 24-month data. Please see full prescribing information. IES Bone Subprotocol 027 No patient with normal BMD at baseline developed osteoporosis while on therapy − 2.59 − 4.57 − 0.33 − 4.15 Femoral Neck (%) − 2.35 − 3.51 − 0.18 − 3.14 Lumbar Spine (%) Placebo n=65 Exemestane n=59 Tamoxifen n=38 Exemestane n=29 BMD*
  • 30. IES Trial 35-Month Follow-up Conclusions
    • Switching to AROMASIN ® after 2 to 3 years of tamoxifen results in significantly improved DFS and was generally safe and well tolerated
    Please see full prescribing information.
  • 31. IES 52.4-Month Update
  • 32. IES: 52.4-Month Update Overview
    • Median follow-up at 52.4 months
      • DFS events: 354 on AROMASIN ® ; 453 on tamoxifen
      • OS events: 222 on AROMASIN ® ; 262 on tamoxifen
    • Median duration of follow-up after completion of therapy: 25 months
    • Analyses presented here are for the ITT and ER+/ER unknown patients
    • 122 patients with previously ER unknown disease were subsequently found to be ER-negative; they were not eligible per protocol and were excluded from ER+/ER unknown analysis
    • ER+/ER unknown (as suggested by the IDMC of the study)
      • This subgroup, which specifically excludes ER-negative patients, was proposed by the ICCG CDC and endorsed by the IES IDMC based on the well-established knowledge that ER-negative patients are unlikely to benefit from either treatment
    IDMC=Independent Data Monitoring Committee; ICCG-CDC=International Collaborative Cancer Group Coordinating Data Center. Data on file. Pfizer Inc, New York, NY. Please see full prescribing information.
  • 33. ASCO 2006 and This Presentation SC=steering committee. *Excluding patients subsequently confirmed with ER negativity. Data on file. Pfizer Inc, New York, NY. Coombes et al. Presented at: the American Society of Clinical Oncology Annual Meeting; June 2-6, 2006; Atlanta, Ga. 484 (Date of death for 1 more pt now available) 483 OS events 807 (1 ipsilateral breast now angiosarcoma) 808 DFS events 52.4 months (No censoring, same weight to patients dead or alive) 55.7 months Median f/u in surviving patients Same data cutoff used for ASCO presentation ( Feb 27, 2006) IDMC & SC agreed – analyze at 95% ≥ 3 yrs f/u & ER+/unknown * Triggered by Pfizer Clinical Study Report ASCO Presented/published October 2006 June 2006 Date
  • 34. Efficacy Results at 52.4 Months: ITT Population *When interpreting the HR information, it is important to note that on average patients had stopped taking either tamoxifen or AROMASIN ® therapy for 25 months. Data on file. Pfizer Inc, New York, NY. Please see full prescribing information. .07 0.71-1.02 0.85 Overall survival .03 0.70-0.98 0.83 Distant RFS .00041 0.33-0.99 0.57 CLBC .00015 0.67-0.88 0.76 DFS P Value 95% CI HR* ITT Population
  • 35. Efficacy Results at 52.4 Months: ER+/ER Unknown Population *When interpreting the HR information, it is important to note that on average patients had stopped taking either tamoxifen or AROMASIN ® therapy for 25 months. Data on file. Pfizer Inc, New York, NY. Please see full prescribing information. .04 0.69-.99 0.83 Overall survival .02 0.69-0.97 0.82 Distant RFS .027 0.31-0.94 0.54 CLBC .00008 0.65-0.87 0.75 DFS P Value 95% CI HR* ER+/ER Unknown Population
  • 36. Disease-Free Survival: 52.4 Months Patients, DFS (%) 1.0 0.8 0.6 0.4 0.2 0 0 20 40 60 10 30 50 80 AROMASIN ® ITT Population Tamoxifen HR = 0.76 (0.67-0.88) P = .00015 70 Months From Randomization Data on file. Pfizer Inc, New York, NY. Please see full prescribing information. 19% 453 Tamoxifen (n = 2372) 15% 354 AROMASIN (n = 2352) Patients Events Median follow-up: 52 months Median duration of therapy: 30 months
  • 37. Disease-Free Survival: 52.4 Months HR = 0.75 (0.65-0.87) P = .00008 1.0 0.8 0.6 0.4 0.2 0 ER+/ER Unknown Population Months From Randomization AROMASIN ® Tamoxifen Patients, DFS (%) Data on file. Pfizer Inc, New York, NY. Please see full prescribing information. 0 20 40 60 10 30 50 80 70 19% 437 Tamoxifen (n = 2306) 15% 338 AROMASIN (n = 2295) Patients Events Median follow-up: 52 months Median duration of therapy: 30 months
  • 38. Overall Survival: 52.4 Months HR = 0.85 (0.71-1.02) P = .07 1.0 0.8 0.6 0.4 0.2 0 Months From Randomization AROMASIN ® Tamoxifen ITT Population Patients Surviving (%) Data on file. Pfizer Inc, New York, NY. Please see full prescribing information. 0 20 40 60 10 30 50 80 70 11% 262 Tamoxifen (n = 2372) 9% 222 AROMASIN (n = 2352) Patients Events Median follow-up: 52 months Median duration of therapy: 30 months
  • 39. Overall Survival: 52.4 Months Months From Randomization 1.0 0.8 0.6 0.4 0.2 0.0 0 20 40 60 10 30 50 80 Tamoxifen AROMASIN ® HR = 0.83 (0.69-0.99) P = .043 ER+/ER Unknown Population 70 Patients Surviving (%) Data on file. Pfizer Inc, New York, NY. Please see full prescribing information. 11% 252 Tamoxifen (n = 2306) 9% 209 AROMASIN (n = 2295) Patients Events Median follow-up: 52 months Median duration of therapy: 30 months
  • 40. Adverse Events: 52.4 Months * P values achieving significance. Data on file. Pfizer Inc, New York, NY. Please see full prescribing information. 4.7% 6.4% Pain in limb 6.1% 5.7% Weight increased 5.6% 6.2% Depression 7.7% 9.3% Back pain 9.1% 8.9% Nausea 8.4% 9.9% Hypertension 8.8% 10.0% Dizziness 9.0% 12.9% Insomnia* 10.6% 12.0% Sweating increased 11.2% 13.6% Headache 10.8% 17.6% Arthralgia* 15.1% 16.3% Fatigue 20.1% 21.8% Hot flushes 82.8% 84.7% Subjects with any illness or AE Tamoxifen (n=2279) AROMASIN ® (n=2249) MedDRA Preferred Term
  • 41. Adverse Events: 52.4 Months (cont’d) * P values achieving significance. Data on file. Pfizer Inc, New York, NY. Please see full prescribing information. 4.9% 7.0% Fracture rate* <0.1% 0.7% Gastric ulcer* 0.9% <0.1% Endometrial hyperplasia* 0.8% 0.2% Uterine polypectomy* 1.8% 0.4% Uterine polyp* 1.8% 0.7% Thromboembolism* 0.2% 2.8% Carpal tunnel syndrome* 1.0% 2.8% Paraesthesia* 3.2% 1.4% Muscle cramp* 2.2% 4.2% Diarrhea* 2.9% 5.2% Osteoporosis* 5.3% 4.0% Vaginal hemorrhage 82.8% 84.7% Subjects with any illness or AE Tamoxifen (n=2279) AROMASIN ® (n=2249) MedDRA Preferred Term
  • 42. Cardiovascular Events: 52.4 Months * P values achieving significance. Data on file. Pfizer Inc, New York, NY. Please see full prescribing information. < 0.1% < 0.1% Pulmonary embolism 2.2% 0.8% Deep vein thrombosis* 2.2% 0.9% Venous thromboembolic event* 5.3% 4.9% Other cardiovascular event 0.4% 0.6% Peripheral vascular disease 8.5% 10.0% Hypertension 0.8% 1.0% Heart failure 13.6% 15.2% Other cardiovascular event 0.2% 0.1% Other isch. cerebrovasc. dis. 0.3% 0.5% Transient ischemic attack 0.5% 0.3% Stroke 1.0% 0.8% Ischemic cerebrovascular dis. 0.1% 0.3% Other ischemic CVD 0.1% 0.4% Myocardial infarction 4.0% 4.1% Angina 4.2% 4.5% Ischemic cardiovascular disease Tamoxifen (n=2279) AROMASIN ® (n=2249)
  • 43. Conclusions: 52.4-Month Update
    • At 25 months after the completion of therapy, switching to AROMASIN ® (exemestane) showed significant improvement in DFS in early breast cancer patients treated with 2 to 3 years of tamoxifen
    • Switching to AROMASIN reduced the risk of dying by 15% for the ITT population ( P =.07) and by 17% in ER+/ER unknown early breast cancer ( P =.04)
    • AROMASIN was generally safe and well tolerated after 52.4 months.
    Please see full prescribing information.
  • 44. AROMASIN ® (exemestane) Adjuvant Indication
    • AROMASIN is indicated for adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer who have received 2 to 3 years of tamoxifen and are switched to AROMASIN for completion of a total of 5 consecutive years of adjuvant hormonal therapy.
    Please see full prescribing information.
  • 45. Important Safety Considerations
    • AROMASIN ® (exemestane) should not be used in women who are
      • Premenopausal
      • Nursing or pregnant
      • Known to be hypersensitive to the drug
      • Taking estrogen-containing agents
    • For patients receiving exemestane with a potent CYP 3A4 inducer, such as rifampicin or phenytoin, the recommended dose of exemestane is 50 mg qd after a meal
    • In patients with early breast cancer, elevations in bilirubin, alkaline phosphatase, and creatinine were more common in those receiving AROMASIN
    • Reductions in BMD over time are seen with use of AROMASIN
    Please see full prescribing information.